Detalhe da pesquisa
1.
The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma.
Blood
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728430
2.
Defining the undetectable: The current landscape of minimal residual disease assessment in multiple myeloma and goals for future clarity.
Blood Rev
; 46: 100732, 2021 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32771227
3.
Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities.
Nat Commun
; 12(1): 1861, 2021 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33767199
4.
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing: Feasibility, Challenges, and Direct Comparison with High-Sensitivity Flow Cytometry.
J Mol Diagn
; 23(2): 181-199, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33217553
5.
Accelerated single cell seeding in relapsed multiple myeloma.
Nat Commun
; 11(1): 3617, 2020 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-32680998
6.
Author Correction: Accelerated single cell seeding in relapsed multiple myeloma.
Nat Commun
; 12(1): 591, 2021 Jan 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33473129
7.
Role of AID in the temporal pattern of acquisition of driver mutations in multiple myeloma.
Leukemia
; 34(5): 1476-1480, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31836853